Coherus loses challenge to AbbVie Humira patent; shares down 5%; AbbVie up 6%

Sep. 07, 2017 1:14 PM ETCoherus BioSciences, Inc. (CHRS)By: Douglas W. House, SA News Editor8 Comments
  • Coherus BioSciences (NASDAQ:CHRS -4.9%) is under pressure on modestly higher volume after it announced that USPTO denied all four of its petitions for Inter Partes review of AbbVie's (ABBV +6.2%) U.S. Patent No. 9,085,619 protecting HUMIRA (adalimumab).
  • CEO Denny Lanfear says, “While we are disappointed by this outcome, we continue to develop and refine our legal strategies for addressing any patents, including formulation patents, that AbbVie may assert in District Court proceedings."

Recommended For You

Comments (8)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.